Universidad Peruana Cayetano Heredia

Mycoplasma genitalium prevalence, antimicrobial resistance-associated mutations, and coinfections with non-viral sexually transmitted infections in high-risk populations in Guatemala, Malta, Morocco, Peru and South Africa, 2019–2021

Mostrar el registro sencillo del ítem

dc.contributor.author Shipitsyna, Elena
dc.contributor.author Kularatne, Ranmini
dc.contributor.author Golparian, Daniel
dc.contributor.author Müller, Etienne E.
dc.contributor.author Vargas Rivera, Silver Keith
dc.contributor.author Hadad, Ronza
dc.contributor.author Padovese, Valeska
dc.contributor.author Hancali, Amina
dc.contributor.author Alvarez, Christian S.
dc.contributor.author Oumzil, Hicham
dc.contributor.author Camey, Elsy
dc.contributor.author Blondeel, Karel
dc.contributor.author Toskin, Igor
dc.contributor.author Unemo, Magnus
dc.coverage.spatial Clínica genitourinaria, Hospital Mater Dei , Msida, Malta
dc.coverage.spatial Centro de Salud Alberto Barton, Callao, Peru
dc.coverage.spatial Centro de Salud Tahuantinsuyo Bajo, Lima, Peru
dc.coverage.spatial Clínica obstétrica y ginecológica del Hospital Regional de Escuintla, Guatemala
dc.coverage.spatial Centro de Información y Detección Anónima y Gratuita, Asociación Marroquí de Lucha contra el Sida, Rabat, Marruecos
dc.coverage.spatial Clínica para jóvenes Site C,Khayelitsha, Ciudad del Cabo
dc.date.accessioned 2023-03-23T15:49:32Z
dc.date.available 2023-03-23T15:49:32Z
dc.date.issued 2023
dc.identifier.uri https://hdl.handle.net/20.500.12866/13263
dc.description.abstract The prevalence of Mycoplasma genitalium (MG) and MG antimicrobial resistance (AMR) appear to be high internationally, however, prevalence data remain lacking globally. We evaluated the prevalence of MG and MG AMR-associated mutations in men who have sex with men (MSM) in Malta and Peru and women at-risk for sexually transmitted infections in Guatemala, South Africa, and Morocco; five countries in four WHO regions mostly lacking MG prevalence and AMR data, and estimated MG coinfections with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV). Male urine and anorectal samples, and vaginal samples were tested for MG, CT, NG, and TV (only vaginal samples) using Aptima assays (Hologic). AMR-associated mutations in the MG 23S rRNA gene and parC gene were identified using ResistancePlus MG kit (SpeeDx) or Sanger sequencing. In total, 1,425 MSM and 1,398 women at-risk were recruited. MG was detected in 14.7% of MSM (10.0% in Malta and 20.0% Peru) and in 19.1% of women at-risk (12.4% in Guatemala, 16.0% Morocco, 22.1% South Africa). The prevalence of 23S rRNA and parC mutations among MSM was 68.1 and 29.0% (Malta), and 65.9 and 5.6% (Peru), respectively. Among women at-risk, 23S rRNA and parC mutations were revealed in 4.8 and 0% (Guatemala), 11.6 and 6.7% (Morocco), and 2.4 and 3.7% (South Africa), respectively. CT was the most frequent single coinfection with MG (in 2.6% of MSM and 4.5% of women at-risk), compared to NG + MG found in 1.3 and 1.0%, respectively, and TV + MG detected in 2.8% of women at-risk. In conclusion, MG is prevalent worldwide and enhanced aetiological MG diagnosis, linked to clinical routine detection of 23S rRNA mutations, in symptomatic patients should be implemented, where feasible. Surveillance of MG AMR and treatment outcome would be exceedingly valuable, nationally and internationally. High levels of AMR in MSM support avoiding screening for and treatment of MG in asymptomatic MSM and general population. Ultimately, novel therapeutic antimicrobials and/or strategies, such as resistance-guided sequential therapy, and ideally an effective MG vaccine are essential. en_US
dc.language.iso eng
dc.publisher Frontiers
dc.relation.ispartofseries Frontiers in Microbiology
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject M. genitalium prevalence and antimicrobial resistance en_US
dc.subject Mycoplasma genitalium en_US
dc.subject men who have sex with men en_US
dc.subject women at-risk en_US
dc.subject prevalence en_US
dc.subject antimicrobial resistance en_US
dc.subject azithromycin en_US
dc.subject moxifloxacin en_US
dc.subject.mesh Mycoplasma genitalium
dc.subject.mesh Minorías Sexuales y de Género
dc.subject.mesh Mujer
dc.subject.mesh Prevalencia
dc.subject.mesh Farmacorresistencia Microbiana
dc.subject.mesh Azitromicina
dc.subject.mesh Moxifloxacino
dc.title Mycoplasma genitalium prevalence, antimicrobial resistance-associated mutations, and coinfections with non-viral sexually transmitted infections in high-risk populations in Guatemala, Malta, Morocco, Peru and South Africa, 2019–2021 en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.3389/fmicb.2023.1130762
dc.relation.issn 1664-302X


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas